Works matching IS 17561841 AND DT 2016 AND VI 19 AND IP 11


Results: 23
    1
    2
    3

    A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.

    Published in:
    International Journal of Rheumatic Diseases, 2016, v. 19, n. 11, p. 1157, doi. 10.1111/1756-185X.12711
    By:
    • Jani, Rajendrakumar H.;
    • Gupta, Rajiv;
    • Bhatia, Girish;
    • Rathi, Gaurav;
    • Ashok Kumar, Patnala;
    • Sharma, Reena;
    • Kumar, Uma;
    • Gauri, Liyakat A.;
    • Jadhav, Praveen;
    • Bartakke, Girishchandra;
    • Haridas, Vikram;
    • Jain, Dinesh;
    • Mendiratta, Sanjeev K.
    Publication type:
    Article
    4

    Issue Information.

    Published in:
    International Journal of Rheumatic Diseases, 2016, v. 19, n. 11, p. 1039, doi. 10.1111/1756-185X.12766
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23